Jazz Pharmaceuticals Presents New Data at Psych Congress 2024 Confirming Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Benefits in Narcolepsy and Idiopathic Hypersomnia
1. JAZZ presented Phase 4 DUET trial results at Psych Congress. 2. Xywav treatment showed significant improvement in narcolepsy symptoms. 3. Low sodium oxybate linked to better sleep quality for patients. 4. Safety profile of Xywav consistent, with common adverse events reported.